Phase Ib study of talimogene laherparepvec in combination with atezolizumab in patients with triple negative breast cancer and colorectal cancer with liver metastases

BACKGROUND: Talimogene laherparepvec (T-VEC), a first-in-class oncolytic viral immunotherapy, enhances tumor-specific immune activation. T-VEC combined with atezolizumab, which blocks inhibitor T-cell checkpoints, could provide greater benefit than either agent alone. Safety/efficacy of the combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Hecht, J.R., Raman, S.S., Chan, A., Kalinsky, K., Baurain, J.-F., Jimenez, M.M., Garcia, M.M., Berger, M.D., Lauer, U.M., Khattak, A., Carrato, A., Zhang, Y., Liu, K., Cha, E., Keegan, A., Bhatta, S., Strassburg, C.P., Roohullah, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163149/
https://www.ncbi.nlm.nih.gov/pubmed/36863095
http://dx.doi.org/10.1016/j.esmoop.2023.100884

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163149/
https://www.ncbi.nlm.nih.gov/pubmed/36863095
http://dx.doi.org/10.1016/j.esmoop.2023.100884

Ejemplares similares